Discovery and molecular basis of subtype-selective cyclophilin inhibitors.

Saved in:
Bibliographic Details
Title: Discovery and molecular basis of subtype-selective cyclophilin inhibitors.
Authors: Peterson AA; Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.; Howard Hughes Medical Institute, Harvard University, Cambridge, MA, USA., Rangwala AM; Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA., Thakur MK; Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA., Ward PS; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Howard Hughes Medical Institute and Departments of Molecular Biology and Medicine, Massachusetts General Hospital, Boston, MA, USA.; Department of Systems Biology, Harvard Medical School, Boston, MA, USA., Hung C; Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.; Howard Hughes Medical Institute, Harvard University, Cambridge, MA, USA., Outhwaite IR; Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA., Chan AI; Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.; Howard Hughes Medical Institute, Harvard University, Cambridge, MA, USA., Usanov DL; Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.; Howard Hughes Medical Institute, Harvard University, Cambridge, MA, USA., Mootha VK; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Howard Hughes Medical Institute and Departments of Molecular Biology and Medicine, Massachusetts General Hospital, Boston, MA, USA.; Department of Systems Biology, Harvard Medical School, Boston, MA, USA., Seeliger MA; Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA. markus.seeliger@stonybrook.edu., Liu DR; Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA, USA. drliu@fas.harvard.edu.; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA. drliu@fas.harvard.edu.; Howard Hughes Medical Institute, Harvard University, Cambridge, MA, USA. drliu@fas.harvard.edu.
Source: Nature chemical biology [Nat Chem Biol] 2022 Nov; Vol. 18 (11), pp. 1184-1195. Date of Electronic Publication: 2022 Sep 26.
Publication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101231976 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4469 (Electronic) Linking ISSN: 15524450 NLM ISO Abbreviation: Nat Chem Biol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1552-4469
DOI:10.1038/s41589-022-01116-1